[Recent progress in developing of thrombolytic agents for ischemic stroke].

Abstract

Ischemic stroke is a major health crisis causing high mortality and morbidity. The key treatment relies on the rapid intervention to dissolve thrombus, to reduce bleeding side effect and re-canalize clotted blood vessels using clot lysis drugs. Tissue plasminogen activator (tPA) is the only FDA-approved drug for ischemic stroke, but it has many limitations in clinical use. In recent years, the development of thrombolytic drugs and treatment strategies based on tPA has been progressed rapidly. Here we review the recent progress in this field, including the contributions from us and others, to promote the future development of novel thrombolytic drugs.

• Authors: Yanyan Xu, Shanli Chen, Dan Chen, Shuangzhou Peng, Yuan Cheng, Jinyu Li, Yongkun Li, Longguang Jiang, Cai Yuan, Mingdong Huang
• Journal: Sheng wu gong cheng xue bao = Chinese journal of biotechnology (Sheng Wu Gong Cheng Xue Bao) Vol. 36 Issue 10 Pg. 2029-2039 (Oct 25 2020) ISSN: 1872-2075 [Electronic] China
• PMID: 33169568 (Publication Type: Journal Article, Review)

Chemical References

• Fibrinolytic Agents
• Tissue Plasminogen Activator

Topics

• Brain Ischemia (drug therapy)
• Fibrinolytic Agents (therapeutic use)
• Humans
• Research (trends)
• Stroke (drug therapy)
• Thrombolytic Therapy (trends)
• Tissue Plasminogen Activator (therapeutic use)